<DOC>
	<DOCNO>NCT03052400</DOCNO>
	<brief_summary>Randomized , double blind , placebo-controlled clinical trial examine efficacy safety mifepristone 600 mg daily male subject type 2 diabetes mellitus , associate Cushing 's syndrome , sub-optimally controlled oral anti-hyperglycemic agent</brief_summary>
	<brief_title>Efficacy Mifepristone Males With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Randomized , double blind , placebo-controlled clinical trial examine efficacy safety mifepristone 600 mg daily male subject type 2 diabetes mellitus , associate Cushing 's syndrome , sub-optimally control metformin without sulfonylurea agent .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Males Age 1865 inclusive Established T2DM ≥ 1 year Taking maximally tolerate dos metformin without sulfonylurea agent Baseline hemoglobin A1c ( HbA1c ) 7.5 % 10.0 % No use antihyperglycemic agent metformin sulfonylureas No current previous chronic use insulin ( ≥ 1 week hospitalization ) No history clinical suspicion type 1 diabetes mellitus No concurrent chronic use corticosteroid route indication , concurrent condition may require initiation glucocorticoid study No concurrent lipidlowering medication whose level dependent CYP3A pathway clearance ( e.g. , simvastatin , lovastatin , atorvastatin , fluvastatin rosuvastatin ) either wash least one month prior enrollment and/or switch alternative LDLcholesterol lower agent ( e.g. , pravastatin ezetimibe ) least one month . No contraindication know intolerance mifepristone No concurrent use strong CYP3A inhibitor ( e.g. , cyclosporine , ergotamine , fentanyl , quinidine , sirolimus , tacrolimus , imidazole antifungal , HIV protease inhibitor , certain macrolide antibiotic ) No concurrent use CYP3A inducer ( e.g. , phenytoin , phenobarbital , carbamazepine , rifampin ) No concurrent use medication may prolong QT interval ( e.g. , select antipsychotic antidepressant , quinolone antibiotic ) No daily use warfarin nonsteroidal antiinflammatory agent Baseline K+ Mg+2 within laboratory normal range , without oral K+ and/or Mg+2 supplementation Fasting plasma glucose ( FPG ) average &lt; 280 mg/dL without polyuria polydipsia No symptomatic hypoglycemia average &gt; per day Mean BP &lt; 140 mmHg systolic 90 mm Hg diastolic Baseline LDLcholesterol &lt; 200 mg/dL lipidlowering therapy &lt; 250 mg/dL lipidlowering therapy Fasting triglyceride ≤ 500 mg/dL lipidlowering therapy HDLcholesterol ≥ 25 mg/dL No known history prostate cancer , elevate level prostatespecific antigen ( PSA ) screen Estimated GFR ≥ 30 mL/min No concurrent endocrinopathies stabilize replacement definitive therapy ( include know adrenal insufficiency regardless replacement therapy , cortisol &lt; 5 μg/dL screen ) No active hemolytic anemia hemoglobin variant render measurement HbA1c potentially unreliable No clinically significant hepatic , cardiovascular ( include know personal family history , risk factor longQT syndrome , QTcF prolongation ECG &gt; 500 m ) , infectious ( include HIV viral hepatitis ) , inflammatory , neoplastic systemic disease may contraindicate change lipidlowering therapy , render mifepristone unsafe , otherwise confound data interpretation Subjects likely start drug may influence study 's outcome ( e.g. , weight loss agent ) Subjects able willing comply component study protocol , attend schedule followup visit , present foreseeable barrier might make implementation protocol problematic confound data interpretation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>mifepristone</keyword>
	<keyword>glucocorticoid</keyword>
</DOC>